SERNIVO (nda208079)- (EQ 0.05% BASE/SPRAY)

Generic Name	BETAMETHASONE DIPROPIONATE	Innovator	PRIMUS PHARMS
Dosage	EQ 0.05% BASE/SPRAY
ParaIV Filing	Yes	505(b)2 Filing	Yes
Last Patent Expiry	2030-Aug-31	NCE Excl Expiry	Expired
ODE Expiry	None	NP Expiry	None
GAIN Expiry	None	Drug Complexity	No
Indication	SERNIVO Spray is a corticosteroid indicated for the treatment of mild to moderate plaque psoriasis in patients 18 years of age or older.

Approvals and Launches

Final Approvals	Tentative Approvals	Generic Launches
0	0	0

Other Developers

Total Other Developers	None

Drugs with Suitability

Drugs with Suitability	No

Drug Pricing

	NDA			ANDA
Dosage	Weekly	Monthly	Yearly	Yearly Up	Yearly Down
EQ 0.05% BASE/SPRAY	**	**	-	-	-

Drug Sales

NDA Sales Available	Total Generic Sales Available
No	0

Manufacturing Details of SERNIVO